GLP-1 weight loss drugs like Ozempic, Zepbound and Wegovy are key contributors to rising prescription spending. That may ...

A recent survey found that up to 4 in 10 employers intend to cover GLP-1 drugs in 2024, up from the 25% of employers that currently cover the medications. Employer sentiment toward GLP-1 drugs showed ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Doesn’t it sound like we all speak pharmacy lingo these ...

Despite the boom in popularity of expensive GLP-1 drugs to treat weight loss, fewer than one in five large employers are covering such prescriptions, a new KFF analysis shows. In this photo is Ozempic ...

As demand for GLP-1s skyrockets, employers are struggling with the cost to cover these expensive medications for their employees. That’s why the Peterson Health Technology Institute, an independent ...

Employer cost coverage increases likelihood of GLP-1 use (65% overall), peaking in ages 35–44 (75%) and declining sharply among workers ≥65 (37%). Behavioral support programs shift willingness to self ...

While 81% of human resource decision-makers feel their employees would be interested in GLP-1 weight-loss medications, only 25% cover GLP-1s currently – but that figure is expected to double next year ...

Eli Lilly has launched Employer Connect, a platform that offers employers a direct route to offer Zepbound coverage to workers at a list price of $449 per month, bypassing traditional pharmacy ...